Last checked at 5 Apr 2024 07:00
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Conversion Notice and Total Voting Rights
5 April 2024 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health, announces that it received a Conversion Notice on 28 March 2024 from Macquarie ("Macquarie") for £500,000 of Convertible Bonds from the £5.0 million convertible bond facility announced on 25 January 2024. The Company has drawn a total of £1.6 million under the Facility and further commited to cap the facility at this amount.
SkinBioTherapeutics will issue 7,583,958 ordinary shares of £0.01 per share ("Ordinary Shares") at a conversion price of 6.592863p per Ordinary Share.
Long term shareholders, including Tyndall Investement Management who have invested in the Company since IPO, have agreed to purchase the shares directly from Macquarie Bank.
Stuart Ashman, CEO of SkinBioTherapeutics said: "This conversion means that £0.71m of the £1.6m we drew down for the acquisition of Dermatonics has converted. We appreciate the continued support we have received from the shareholders who have been with us since IPO. We see this as a validation of what we have achieved so far and the ongoing strategy to build scale and financial strength."
Admission and Total Voting Rights
Application has been made for the 7,583,958 new ordinary shares, which will rank pari passu in all respects with the existing ordinary shares of the Company, to be admitted to AIM, which is expected to occur on or around 8.00 a.m. on 8 April 2024 ("Admission"). Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 200,379,907.
The above figure of 200,379,907 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
-Ends-
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.
For more information please contact:
SkinBioTherapeutics plc Stuart J. Ashman, CEO Manprit Randhawa, CFO
| Tel: +44 (0) 191 495 7325
|
Cavendish Capital Markets Limited (Nominated Adviser & Broker) Giles Balleny, Dan Hodkinson (Corporate Finance) Charlie Combe (Broking) Dale Bellis, Tamar Cranford-Smith (Sales)
| Tel: +44 (0) 20 7220 0500 |
Instinctif Partners (financial press) Melanie Toyne-Sewell / Jack Kincade | Tel: +44 (0) 20 7457 2020 SkinBioTherapeutics@instinctif.com |
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.
The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.